0001157523-21-001297.txt : 20211101 0001157523-21-001297.hdr.sgml : 20211101 20211101160222 ACCESSION NUMBER: 0001157523-21-001297 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20211101 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211101 DATE AS OF CHANGE: 20211101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HOLOGIC INC CENTRAL INDEX KEY: 0000859737 STANDARD INDUSTRIAL CLASSIFICATION: X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844] IRS NUMBER: 042902449 STATE OF INCORPORATION: DE FISCAL YEAR END: 0928 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36214 FILM NUMBER: 211367106 BUSINESS ADDRESS: STREET 1: 250 CAMPUS DRIVE CITY: MARLBOROUGH STATE: MA ZIP: 01752 BUSINESS PHONE: 5082632900 MAIL ADDRESS: STREET 1: 250 CAMPUS DRIVE CITY: MARLBOROUGH STATE: MA ZIP: 01752 8-K 1 a52518777.htm HOLOGIC, INC. 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K


Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) November 1, 2021
 

HOLOGIC, INC.
(Exact Name of Registrant as Specified in Its Charter)
 

Delaware
(State or Other Jurisdiction of Incorporation)
   
001-36214
04-2902449
(Commission File Number)
(I.R.S. Employer Identification No.)

250 Campus Drive, Marlborough, Massachusetts
01752
(Address of Principal Executive Offices)
(Zip Code)
 
(508) 263-2900
(Registrant’s Telephone Number, Including Area Code)
 
(Former Name or Former Address, if Changed Since Last Report)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Common Stock, $.01 par value   HOLX
   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
 
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02  Results of Operations and Financial Condition.
 
On November 1, 2021, Hologic, Inc. issued a press release announcing its financial results for the fourth quarter and year ended September 25, 2021. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.
Limitation on Incorporation by Reference. The information furnished in this Item 2.02, including the press release attached hereto as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as set forth by specific reference in such a filing.  
Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in the press release attached as an exhibit hereto, the press release contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary note in the press release regarding these forward-looking statements.
 
Item 9.01  Financial Statements and Exhibits.
 
(d) Exhibits.
 
     
Exhibit
Number
 
Description
 
     
104
  
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
Date: November 1, 2021
 

HOLOGIC, INC.
     
     
 
By:
/s/ Karleen M. Oberton
 
 
Karleen M. Oberton
 
 
Chief Financial Officer
 

 EX-99.1 2 a52518777_ex991.htm EXHIBIT 99.1
Exhibit 99.1

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2021

– Revenue of $1.317 Billion Exceeds Expectations –

– Company Posts GAAP Diluted EPS of $1.28, Non-GAAP Diluted EPS of $1.61 –

– Financial Guidance for Fiscal 2022 Anticipates Solid Growth in Core Women’s Health Businesses and Continued Contributions to COVID-19 Fight –

MARLBOROUGH, Mass.--(BUSINESS WIRE)--November 1, 2021--Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal fourth quarter ended September 25, 2021.

“Our excellent top- and bottom-line results in the fourth quarter of fiscal 2021 exceeded expectations and capped off a remarkable year,” said Steve MacMillan, the Company’s chairman, president and chief executive officer. “In 2021, we lived into our Purpose, Passion and Promise by showcasing our team’s incredible ability to respond simultaneously to the world’s women’s health and COVID-19 testing needs, which drove annual revenue growth of 47% to more than $5.6 billion.”

Recent Highlights

  • Revenue of $1.317 billion decreased (2.3%) for the quarter, or (2.9%) in constant currency, driven by lower sales of COVID-19 assays compared to the prior year period.
  • Excluding significant acquisitions, organic revenue of $1.266 billion in the quarter decreased (5.4%), or (6.0%) in constant currency.
  • Excluding revenue from COVID-19 assays and related products such as collection kits, organic revenue grew 12.0% on a constant currency basis, which compares favorably to the long-term goal of 5% to 7% growth that the Company outlined in its last quarterly earnings call.
  • Global revenue for the Company’s Breast Health and GYN Surgical divisions grew 15.6% and 21.8%, or 15.1% and 20.9% in constant currency, respectively, as the businesses recovered strongly compared to the prior year period, when sales were negatively affected by the COVID-19 pandemic.
  • Global diagnostics revenue of $836.8 million decreased (10.9%), or (11.5%) in constant currency, driven by lower sales of COVID-19 assays. However, excluding revenue from COVID-19 assays and related products, global diagnostics revenue grew 5.1% on an organic, constant currency basis. Similarly, global molecular diagnostics revenue of $704.5 million declined (14.0%), or (14.5%) in constant currency, yet grew 6.5% on an organic, constant currency basis excluding sales of COVID-19 assays and related products.
  • Consistent with the Company’s capital allocation strategy, announced the acquisition of Bolder Surgical, a private, U.S.-based company that provides advanced energy vessel sealing surgical devices, for approximately $160 million.
  • Released results of the inaugural Hologic Global Women’s Health Index, the world’s most comprehensive, globally comparative survey about women’s health. Developed in partnership with Gallup, the Index is an unprecedented, in-depth examination of critical markers for women’s health, by country and territory, and over time.
  • Launched across Europe the Novodiag system, a fully automated molecular diagnostics solution for on-demand testing of infectious diseases and antimicrobial resistance. The launch follows the Company’s acquisition of Mobidiag Oy in June 2021.
  • Cash flow from operations was a very strong $465.4 million in the fourth quarter. For the full fiscal year, the Company generated more than $2.3 billion of operating cash flow.
  • Investor’s Business Daily named Hologic one of their “100 Best ESG Stocks.”

Key financial results for the fiscal fourth quarter are shown in the table below.

 


GAAP

 

Non-GAAP

 


Q4’21


Q4’20


Change
Increase
(Decrease)

 

Q4’21


Q4’20


Change
Increase
(Decrease)

Revenues


$1,316.6


$1,347.0


(2.3%)

 

$1,316.6


$1,347.0


(2.3%)

Gross Margin


62.9%


69.2%


(630 bps)

 

69.4%


74.2%


(480 bps)

Operating Expenses


$388.6


$299.0


30.0%

 

$353.2


$276.6


27.7%

Operating Margin


33.4%


47.0%


(1,360 bps)

 

42.5%


53.7%


(1,120 bps)

Net Margin


25.0%


36.6%


(1,160 bps)

 

31.6%


40.4%


(880 bps)

Diluted EPS


$1.28


$1.88


(31.9%)

 

$1.61


$2.07


(22.2%)

Throughout this press release, all dollar figures are in millions, except EPS, unless otherwise noted. Some totals may not foot due to rounding. Unless otherwise noted, all results are compared to the corresponding prior year period. Non-GAAP results exclude certain cash and non-cash items as discussed under “Use of Non-GAAP Financial Measures.” Constant currency percentage changes show current period revenue results as if the foreign exchange rates were the same as those in the prior year period. For fiscal 2021, organic revenue excludes the divested Blood Screening business, as well as the acquired Acessa, Biotheranostics, Diagenode and Mobidiag businesses. Revenue from acquired businesses is generally included in organic revenue starting a year after the acquisition.

Revenue Detail

 


 


 


Increase (Decrease)

$ in millions


Q4’21


Q4’20


Global
Reported
Change


Global
Constant
Currency
Change


U.S.
Reported
Change


International
Reported
Change


International
Constant
Currency
Change

Diagnostics


 


 


 


 


 


 


 

Cytology & Perinatal


$116.0


$111.4


4.1%


3.1%


(1.8%)


16.3%


13.4%

Molecular Diagnostics


$704.5


$818.9


(14.0%)


(14.5%)


(19.0%)


(0.9%)


(3.0%)

Blood Screening


$16.3


$8.7


87.4%


87.4%


87.4%


N/A


N/A

Total Diagnostics


$836.8


$939.0


(10.9%)


(11.5%)


(15.7%)


1.4%


(0.7%)

Excluding Blood


$820.5


$930.3


(11.8%)


(12.4%)


(17.1%)


1.4%


(0.7%)

 


 


 


 


 


 


 


 

Breast Health


 


 


 


 


 


 


 

Breast Imaging


$265.5


$235.5


12.7%


12.3%


16.5%


0.3%


(1.8%)

Interventional Breast Solutions


$68.7


$53.7


27.9%


27.3%


22.2%


62.5%


58.8%

Total Breast Health


$334.2


$289.2


15.6%


15.1%


17.7%


7.9%


5.6%

 


 


 


 


 


 


 


 

GYN Surgical


$122.0


$100.2


21.8%


20.9%


20.8%


26.9%


21.5%

 


 


 


 


 


 


 


 

Skeletal Health


$23.6


$18.6


26.9%


26.2%


37.5%


7.3%


6.6%

 


 


 


 


 


 


 


 

Total


$1,316.6


$1,347.0


(2.3%)


(2.9%)


(4.4%)


3.9%


1.6%

Excluding divested Blood business and Acessa,Biotheranostics, Diagenode and Mobidiag acquisitions (organic)


$1,265.9


$1,338.0


(5.4%)


(6.0%)


(7.4%)


0.3%


(2.0%)

Other Financial Highlights

  • U.S. revenue of $950.6 million decreased (4.4%). International revenue of $366.0 million increased 3.9%, or 1.6% in constant currency. Organically, U.S. revenue of $912.6 million decreased (7.4%), while international revenue of $353.2 million increased 0.3%, a decrease of (2.0%) in constant currency.
  • GAAP gross margin of 62.9% decreased (630) basis points. Non-GAAP gross margin of 69.4% decreased (480) basis points. The decrease in gross margin was primarily due to a decline in COVID-19 assay sales compared to the prior year period.
  • GAAP operating margin of 33.4% decreased (1,360) basis points. Non-GAAP operating margin of 42.5% decreased (1,120) basis points. The decrease in operating margin was primarily due to a decline in COVID-19 assay sales compared to the prior year period.
  • GAAP net income attributable to Hologic of $328.8 million decreased (33.7%). Non-GAAP net income attributable to Hologic of $415.7 million decreased (23.5%). Adjusted non-GAAP earnings before interest, taxes, depreciation and amortization (EBITDA) was $575.8 million, a decrease of (23.1%).
  • COVID-19 assay revenue of $443.3 million decreased (26.3%), or (26.8%) in constant currency. COVID-19 related revenue, which is revenue from products such as collection kits that depends in part on COVID-19 test demand, was $63.8 million in the fourth quarter, an increase of 1.1%, or 0.7% in constant currency, compared to the prior year period.
  • Total principal debt outstanding at the end of the fourth quarter was $3.05 billion. The Company ended the quarter with cash and equivalents of $1.17 billion, and a net leverage ratio (net debt over adjusted EBITDA) of 0.6.
  • On a trailing 12 months basis, adjusted Return on Invested Capital (ROIC) of 32.6% increased 1,410 basis points compared to the prior year period.

Financial Guidance for Fiscal 2022

“We expect strong financial results in fiscal 2022, with solid growth in our core women’s health businesses and a meaningful contribution from COVID-19 testing,” said Karleen Oberton, Hologic’s chief financial officer.

Hologic’s financial guidance for the first quarter and full year 2022 is shown in the table below. The guidance is based on a full year non-GAAP tax rate of approximately 21.5%, and diluted shares outstanding of 260 million for the full year. Constant currency guidance assumes that foreign exchange rates are the same in fiscal 2022 as in fiscal 2021. Organic revenue guidance is in constant currency, and excludes the divested Blood Screening business. Revenue from acquired businesses is generally included in organic revenue guidance starting a year after the acquisition. Therefore, in fiscal 2022, Acessa will be included in organic revenue for the full year, Biotheranostics and Diagenode will become part of organic revenue in the fiscal third quarter, and Mobidiag will become part of organic revenue in the fiscal fourth quarter. The guidance below does not include the impact of the Bolder Surgical acquisition, which has not closed.

 


Guidance for Fiscal 2022

 


Guidance $

Reported % Increase
(Decrease)

Constant Currency
% Increase (Decrease)

Organic % Increase
(Decrease)

Fiscal 2022


 

 

 

 

Revenue


$3,750 - $4,000

(33.4%) to (29.0%)

(33.0%) to (28.5%)

(34.1%) to (29.6%)

GAAP EPS


$2.50 - $2.80

(65.3%) to (61.2%)

 

 

Non-GAAP EPS


$3.55 - $3.85

(57.8%) to (54.2%)

 

 



 

 

 

 

Q1 2022


 

 

 

 

Revenue


$1,100 - $1,150

(31.7%) to (28.6%)

(31.5%) to (28.4%)

(33.5%) to (30.4%)

GAAP EPS


$0.88 - $0.98

(64.8%) to (60.8%)

 

 

Non-GAAP EPS


$1.15 - $1.25

(59.8%) to (56.3%)

 

 

Use of Non-GAAP Financial Measures

The Company has presented the following non-GAAP financial measures in this press release: constant currency revenues; organic revenues; organic revenues excluding COVID related revenues, non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective tax rate; non-GAAP net income; non-GAAP net margin; non-GAAP EPS; and adjusted EBITDA. For fiscal 2021, organic revenue excludes the divested Blood Screening business, as well as the acquired Acessa, Biotheranostics, Diagenode and Mobidiag businesses. Revenue from acquired businesses is generally included in organic revenue starting a year after the acquisition. The Company defines its non-GAAP net income, EPS, and other non-GAAP financial measures to exclude, as applicable: (i) the amortization of intangible assets and impairment of goodwill, intangible assets and equipment; (ii) adjustments to record contingent consideration at fair value; (iii) additional expenses resulting from the purchase accounting adjustment to record inventory at fair value; (iv) restructuring and divestiture charges and facility closure and consolidation charges, including accelerated depreciation, and costs incurred to integrate acquisitions (including retention, transaction bonuses, legal and professional consulting services) and separate divested businesses from existing operations; (v) expenses related to the divested Cynosure business incurred subsequent to the disposition date primarily related to indemnification provisions for legal and tax matters; (vi) transaction related expenses for divestitures and acquisitions; (vii) third-party expenses incurred related to implementing the European MDR/IVDR requirements and obtaining the appropriate approvals for its existing products; (viii) debt extinguishment losses and related transaction costs; (ix) the unrealized (gains) losses on the mark-to-market of foreign currency contracts for which the Company has not elected hedge accounting; (x) litigation settlement charges (benefits) and non-income tax related charges (benefits); (xi) other-than-temporary impairment losses on investments and realized gains and losses resulting from the sale of investments; (xii) the one-time discrete impacts related to internal restructurings and non-operational items; (xiii) other one-time, non-recurring, unusual or infrequent charges, expenses or gains that may not be indicative of the Company's core business results; and (xiv) income taxes related to such adjustments. The Company defines adjusted EBITDA as its non-GAAP net income plus net interest expense, income taxes, and depreciation and amortization expense included in its non-GAAP net income.

These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. The Company's definition of these non-GAAP measures may differ from similarly titled measures used by others.

The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of Hologic's historical operating results, comparison to competitors' operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting Hologic's business.

Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.

Conference Call and Webcast

Hologic’s management will host a conference call at 4:30 p.m. ET today to discuss its financial results for the fourth quarter of fiscal 2021. Interested participants may listen to the call by dialing 800-458-4121 (in the U.S. and Canada) or +1 323-794-2093 (for international callers) and referencing access code 2820462. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. A replay will be available approximately two hours after the call ends through Friday, December 3, 2021. The replay numbers are 888-203-1112 (U.S.) or +1 719-457-0820 (international), access code 2820462, PIN 3270. The Company will also provide a live webcast of the call at investors.hologic.com.

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statements

This news release contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; the Company’s strategies, positioning, resources, capabilities, and expectations for future performance; and the Company's outlook and financial and other guidance. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.

Risks and uncertainties that could adversely affect the Company’s business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation: the severity and duration of the COVID-19 pandemic and its impact on the U.S. healthcare system, the U.S. economy and worldwide economy; the timing, scope and effect of further U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic; continued demand for the Company’s COVID-19 TMA assay; the Company’s ability to manufacture, on a scale necessary to meet demand, its COVID-19 TMA assay as well as the Panther systems on which the assay runs; U.S., European and general worldwide economic conditions, trade relations, and related uncertainties; disruption of supply chains, including the availability of critical raw materials and components, as well as cost inflation in raw materials, packaging and transportation; manufacturing risks, including the Company’s reliance on a single or limited source of supply for key components, the need to comply with especially high standards for the manufacture of many of its products and risks associated with utilizing third party manufacturers; the Company’s ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the ability of the Company to successfully manage leadership and organizational changes, including the ability of the Company to attract, motivate and retain key employees and maintain engagement and efficiency in remote work environments; the Company’s reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; changes to applicable laws and regulations, including tax laws, global health care reform, and import/export trade laws; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the Company’s products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the Company to realize anticipated benefits of those alliances; risks associated with acquisitions, including, without limitation, the Company’s ability to successfully integrate acquired businesses, the risks that the acquired businesses may not operate as effectively and efficiently as expected even if otherwise successfully integrated, and the risks that acquisitions may involve unexpected costs or unexpected liabilities; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the Company’s international activities and businesses; the early stage of market development for certain of the Company’s products; the Company’s leverage risks, including the Company’s obligation to meet payment obligations and financial covenants associated with its debt; cybersecurity risks; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; technical innovations that could render products marketed or under development by the Company obsolete; and competition.

The risks included above are not exhaustive. Other factors that could adversely affect the Company's business and prospects are described in the filings made by the Company with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

SOURCE: Hologic, Inc.

HOLOGIC, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

(In millions, except number of shares, which are reflected in thousands, and per share data)





 

 


Three Months Ended

 

Years Ended

 


September 25,
2021

 

September 26,
2020

 

September 25,
2021

 

September 26,
2020

 


 

 

 

 

 

 

 

Revenues:


 

 

 

 

 

 

 

Product


$

1,137.9

 

 

$

1,202.5

 

 

$

4,967.3

 

 

$

3,227.0

 

Service and other


178.7

 

 

144.5

 

 

665.0

 

 

549.4

 

Total revenues


1,316.6

 

 

1,347.0

 

 

5,632.3

 

 

3,776.4

 

 


 

 

 

 

 

 

 

Cost of revenues:


 

 

 

 

 

 

 

Product


316.0

 

 

267.8

 

 

1,205.1

 

 

953.7

 

Amortization of acquired intangible assets


82.5

 

 

63.8

 

 

276.7

 

 

253.2

 

Impairment of intangible assets and equipment


—

 

 

—

 

 

—

 

 

25.8

 

Service and other


90.0

 

 

83.6

 

 

354.7

 

 

316.2

 

Gross profit


828.1

 

 

931.8

 

 

3,795.8

 

 

2,227.5

 

 


 

 

 

 

 

 

 

Operating expenses:


 

 

 

 

 

 

 

Research and development


76.5

 

 

57.0

 

 

276.3

 

 

222.5

 

Selling and marketing


159.1

 

 

125.7

 

 

561.2

 

 

484.6

 

General and administrative


135.4

 

 

95.7

 

 

433.2

 

 

355.7

 

Amortization of acquired intangible assets


11.5

 

 

10.2

 

 

42.2

 

 

39.7

 

Impairment of intangible assets and equipment


—

 

 

—

 

 

—

 

 

4.4

 

Contingent consideration fair value adjustments


3.4

 

 

(0.1

)

 

(6.7

)

 

0.3

 

Restructuring and divestiture charges


2.7

 

 

10.5

 

 

9.3

 

 

15.3

 

Total operating expenses


388.6

 

 

299.0

 

 

1,315.5

 

 

1,122.5

 

 


 

 

 

 

 

 

 

Income from operations


439.5

 

 

632.8

 

 

2,480.3

 

 

1,105.0

 

Interest income


0.2

 

 

0.3

 

 

1.4

 

 

4.3

 

Interest expense


(22.7

)

 

(25.0

)

 

(93.6

)

 

(116.5

)

Debt extinguishment loss


—

 

 

—

 

 

(21.6

)

 

—

 

Other income (expense), net


(6.4

)

 

9.0

 

 

(5.4

)

 

9.1

 

 


 

 

 

 

 

 

 

Income before income taxes


410.6

 

 

617.1

 

 

2,361.1

 

 

1,001.9

 

Provision (benefit) for income taxes


81.8

 

 

123.5

 

 

491.4

 

 

(108.6

)

Net income


$

328.8

 

 

$

493.6

 

 

$

1,869.7

 

 

$

1,110.5

 

 


 

 

 

 

 

 

 

Net loss attributable to noncontrolling interest


—

 

 

(1.4

)

 

(1.8

)

 

(4.7

)

Net income attributable to Hologic


$

328.8

 

 

$

495.0

 

 

$

1,871.5

 

 

$

1,115.2

 

 


 

 

 

 

 

 

 

Net income per common share attributable to Hologic:


 

 

 

 

 

 

 

Basic


$

1.29

 

 

$

1.90

 

 

$

7.28

 

 

$

4.24

 

Diluted


$

1.28

 

 

$

1.88

 

 

$

7.21

 

 

$

4.21

 

 


 

 

 

 

 

 

 

Weighted average number of shares outstanding:


 

 

 

 

 

 

 

Basic


254,876

 

 

259,908

 

 

257,046

 

 

262,727

 

Diluted


257,710

 

 

263,179

 

 

259,706

 

 

264,613

 

HOLOGIC, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In millions)





 

 


September 25,
2021

 

September 26,
2020

ASSETS


 

 

 

 


 

 

 

Current assets:


 

 

 

Cash and cash equivalents


$

1,170.3

 

 

$

701.0

 

 

Accounts receivable, net


942.7

 

 

1,028.9

 

 

Inventory


501.2

 

 

395.1

 

 

Other current assets


554.5

 

 

97.3

 

 

Total current assets


3,168.7

 

 

2,222.3

 

 

 


 

 

 

Property, plant and equipment, net


564.7

 

 

491.5

 

 

Goodwill and intangible assets


4,940.8

 

 

3,965.4

 

 

Other assets


245.7

 

 

516.6

 

 

Total assets


$

8,919.9

 

 

$

7,195.8

 

 

 


 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY


 

 

 

 


 

 

 

Current liabilities:


 

 

 

Current portion of long-term debt


$

313.0

 

 

$

324.9

 

 

Accounts payable and accrued liabilities


815.8

 

 

728.3

 

 

Deferred revenue


198.0

 

 

186.1

 

 

Total current liabilities


1,326.8

 

 

1,239.3

 

 

 


 

 

 

Long-term debt, net of current portion


2,712.2

 

 

2,713.9

 

 

Deferred income taxes


250.5

 

 

201.8

 

 

Other long-term liabilities


411.8

 

 

333.5

 

 

Total Hologic stockholders' equity


4,218.6

 

 

2,705.2

 

 

Noncontrolling interest


—

 

 

2.1

 

 

Total liabilities and stockholders’ equity


$

8,919.9

 

 

$

7,195.8

 

 

HOLOGIC, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In millions)



 

 


Years Ended

 


September 25, 2021

 

September 26, 2020

OPERATING ACTIVITIES


 

 

 

Net income


$

1,869.7

 

 

$

1,110.5

 

Adjustments to reconcile net income to net cash provided by operating activities:


 

 

 

Depreciation


88.0

 

 

83.1

 

Amortization


318.9

 

 

292.9

 

Stock-based compensation expense


65.0

 

 

83.3

 

Deferred income taxes


(70.1

)

 

(94.4

)

Intangible asset and equipment impairment charges


—

 

 

30.2

 

Debt extinguishment loss


21.6

 

 

—

 

Other adjustments and non-cash items


24.3

 

 

27.3

 

Changes in operating assets and liabilities, excluding the effect of acquisitions and dispositions:


 

 

 

Accounts receivable


110.9

 

 

(427.1

)

Inventory


(84.1

)

 

(25.3

)

Prepaid income taxes


13.0

 

 

(3.8

)

Prepaid expenses and other assets


(56.3

)

 

(286.2

)

Accounts payable


20.4

 

 

(4.9

)

Accrued expenses and other liabilities


(4.9

)

 

96.0

 

Deferred revenue


14.0

 

 

15.0

 

Net cash provided by operating activities


2,330.4

 

 

896.6

 

INVESTING ACTIVITIES


 

 

 

Acquisition of businesses, net of cash acquired


(1,164.7

)

 

(119.4

)

Net proceeds from sale of business


—

 

 

139.3

 

Purchase of property and equipment


(96.8

)

 

(98.3

)

Increase in equipment under customer usage agreements


(59.4

)

 

(58.1

)

Purchase of intellectual property


(6.5

)

 

—

 

Other activity


(2.2

)

 

(5.1

)

Net cash used in investing activities


(1,329.6

)

 

(141.6

)

FINANCING ACTIVITIES


 

 

 

Repayment of long-term debt


(75.0

)

 

(45.8

)

Proceeds from senior notes, net of issuance costs


936.3

 

 

—

 

Repayment of senior notes


(970.8

)

 

—

 

Proceeds from revolving credit line


—

 

 

750.0

 

Repayments under revolving credit line


(250.0

)

 

(500.0

)

Proceeds from accounts receivable securitization program


320.0

 

 

16.0

 

Repayments under accounts receivable securitization program


(71.5

)

 

(250.0

)

Purchase of non-controlling interest


(8.5

)

 

(1.8

)

Repurchases of common stock


(409.7

)

 

(653.6

)

Payment of deferred acquisition consideration


(1.9

)

 

(24.3

)

Net proceeds from issuance of common stock under employee stock plans


51.3

 

 

65.6

 

Payment of minimum tax withholdings on net share settlements of equity awards


(47.6

)

 

(14.3

)

Payments under finance lease obligations


(2.4

)

 

(1.7

)

Net cash used in financing activities


(529.8

)

 

(659.9

)

Effect of exchange rate changes on cash and cash equivalents


(1.7

)

 

4.1

 

Net increase in cash and cash equivalents


469.3

 

 

99.2

 

Cash and cash equivalents, beginning of period


701.0

 

 

601.8

 

Cash and cash equivalents, end of period


$

1,170.3

 

 

$

701.0

 

HOLOGIC, INC.

RECONCILIATION OF GAAP TO NON-GAAP RESULTS

(Unaudited)

(In millions, except earnings per share and margin percentages)
















 

Reconciliation of GAAP Revenue to Organic Revenue excluding COVID Related Revenues

 

Three Months Ended

 

Years Ended

 

September 25,
2021

 

September 26,
2020

 

September 25,
2021

 

September 26,
2020

Consolidated GAAP Revenue

1,316.6

 

 

1,347.0

 

 

5,632.3

 

 

3,776.4

 

Less: Medical Aesthetics revenue

—

 

 

—

 

 

—

 

 

(65.3

)

Less: Blood Screening revenue

(16.3

)

 

(8.7

)

 

(49.6

)

 

(43.6

)

Less: Revenue from Acessa, Biotheranostics, Diagenode and Mobidiag Oy

(34.4

)

 

(0.3

)

 

(71.7

)

 

(0.3

)

Organic Revenue

$

1,265.9

 

 

$

1,338.0

 

 

$

5,511.0

 

 

$

3,667.2

 

Less: COVID19 Assays

(443.3

)

 

(601.2

)

 

(2,159.5

)

 

(929.3

)

Less: COVID19 Ancillaries *

(63.8

)

 

(63.1

)

 

(275.8

)

 

(150.2

)

Organic Revenue excluding COVID related revenues

$

758.8

 

 

$

673.7

 

 

$

3,075.7

 

 

$

2,587.7

 

*Revenues related to COVID assay sales for instruments, collections kits and ancillaries, as well as license revenue, which are related in part to COVID assay sales.

 

Three Months Ended

 

Years Ended

 

September 25,
2021

 

September 26,
2020

 

September 25,
2021

 

September 26,
2020

 

 

 

 

 

 

 

 

Gross Profit:

 

 

 

 

 

 

 

GAAP gross profit

$

828.1

 

 

$

931.8

 

 

$

3,795.8

 

 

$

2,227.5

 

Adjustments:

 

 

 

 

 

 

 

Amortization of acquired intangible assets (1)

82.5

 

 

63.8

 

 

276.7

 

 

253.2

 

Integration/consolidation costs (3)

—

 

 

2.6

 

 

1.0

 

 

3.2

 

Impairment of intangible assets and equipment (16)

—

 

 

—

 

 

—

 

 

25.8

 

Fair value write-up of acquired inventory sold (13)

2.6

 

 

1.5

 

 

7.9

 

 

6.7

 

Non-GAAP gross profit

$

913.2

 

 

$

999.7

 

 

$

4,081.4

 

 

$

2,516.4

 

 

 

 

 

 

 

 

 

Gross Margin Percentage:

 

 

 

 

 

 

 

GAAP gross margin percentage

62.9

%

 

69.2

%

 

67.4

%

 

59.0

%

Impact of adjustments above

6.5

%

 

5.0

%

 

5.1

%

 

7.6

%

Non-GAAP gross margin percentage

69.4

%

 

74.2

%

 

72.5

%

 

66.6

%

 

 

 

 

 

 

 

 

Operating Expenses:

 

 

 

 

 

 

 

GAAP operating expenses

$

388.6

 

 

$

299.0

 

 

$

1,315.5

 

 

$

1,122.5

 

Adjustments:

 

 

 

 

 

 

 

Amortization of acquired intangible assets (1)

(11.5

)

 

(10.2

)

 

(42.2

)

 

(39.7

)

Transaction expenses (4)

(1.9

)

 

(1.5

)

 

(21.0

)

 

(5.7

)

Contingent consideration adjustments (7)

(3.4

)

 

0.1

 

 

6.7

 

 

(0.3

)

Integration/consolidation costs (3)

(5.6

)

 

(1.4

)

 

(12.9

)

 

(11.8

)

MDR expenses (2)

(2.5

)

 

(1.8

)

 

(9.8

)

 

(2.5

)

Purchased research and development asset charges (18)

—

 

 

—

 

 

(7.0

)

 

—

 

Restructuring and divestiture charges (3)

(2.7

)

 

(10.5

)

 

(9.3

)

 

(15.3

)

Non-income tax charges (benefits) (5)

(7.8

)

 

2.9

 

 

(4.5

)

 

2.9

 

Impairment of intangible assets and equipment (16)

—

 

 

—

 

 

—

 

 

(4.4

)

Acquisition related adjustment (10)

—

 

 

—

 

 

—

 

 

3.8

 

Non-GAAP operating expenses

$

353.2

 

 

$

276.6

 

 

$

1,215.5

 

 

$

1,049.5

 

 

 

 

 

 

 

 

 

Operating Margin:

 

 

 

 

 

 

 

GAAP income from operations

$

439.5

 

 

$

632.8

 

 

$

2,480.3

 

 

$

1,105.0

 

Adjustments to gross profit as detailed above

85.1

 

 

67.9

 

 

285.6

 

 

288.9

 

Adjustments to operating expenses as detailed above

35.4

 

 

22.4

 

 

100.0

 

 

73.0

 

Non-GAAP income from operations

$

560.0

 

 

$

723.1

 

 

$

2,865.9

 

 

$

1,466.9

 

 

 

 

 

 

 

 

 

Operating Margin Percentage:

 

 

 

 

 

 

 

GAAP income from operations margin percentage

33.4

%

 

47.0

%

 

44.0

%

 

29.3

%

Impact of adjustments above

9.1

%

 

6.7

%

 

6.9

%

 

9.5

%

Non-GAAP operating margin percentage

42.5

%

 

53.7

%

 

50.9

%

 

38.8

%












 

Pre-Tax Income:

 

 

 

 

 

 

 

GAAP pre-tax earnings

$

410.6

 

 

$

617.1

 

 

$

2,361.1

 

 

$

1,001.9

 

Adjustments to pre-tax earnings as detailed above

120.5

 

 

 

90.3

 

 

385.6

 

 

361.9

 

Debt extinguishment loss (6)

—

 

 

 

—

 

 

21.6

 

 

—

 

Debt transaction costs (9)

—

 

 

 

—

 

 

5.8

 

 

—

 

Impairment of a cost method investment (14)

1.8

 

 

 

—

 

 

1.8

 

 

—

 

Unrealized (gains) losses on forward foreign currency (8)

(3.4

)

 

 

(5.0

)

 

4.3

 

 

(3.8

)

Other charges (15)

—

 

 

 

—

 

 

—

 

 

(1.0

)

Non-GAAP pre-tax income

$

529.5

 

 

$

702.4

 

 

$

2,780.2

 

 

$

1,359.0

 

 

 

 

 

 

 

 

 

Net Income Attributable to Hologic:

 

 

 

 

 

 

 

GAAP net income

$

328.8

 

 

$

493.6

 

 

$

1,869.7

 

 

$

1,110.5

 

Adjustments:

 

 

 

 

 

 

 

Amortization of acquired intangible assets (1)

94.0

 

 

 

74.0

 

 

318.9

 

 

292.9

 

Impairment of intangible assets and equipment (16)

—

 

 

 

—

 

 

—

 

 

30.2

 

Restructuring and integration/consolidation costs (3)

8.3

 

 

 

14.5

 

 

23.2

 

 

30.2

 

Purchased research and development asset charge (18)

—

 

 

 

—

 

 

7.0

 

 

—

 

MDR expenses (2)

2.5

 

 

 

1.8

 

 

9.8

 

 

2.5

 

Debt extinguishment loss and transaction costs (6) (9)

—

 

 

 

—

 

 

27.4

 

 

—

 

Acquisition related expenses and adjustments (4) (10) (13)

4.5

 

 

 

3.0

 

 

28.9

 

 

8.7

 

Contingent consideration adjustments (7)

3.4

 

 

 

(0.1

)

 

(6.7

)

 

0.3

 

Non-operating (benefit) charges (8) (14) (15)

(1.6

)

 

 

(5.0

)

 

6.1

 

 

(4.8

)

Non-income tax charges (benefits) (5)

7.8

 

 

 

(2.9

)

 

4.5

 

 

(2.9

)

Discrete tax benefit from sale of Cynosure (17)

—

 

 

 

(0.6

)

 

—

 

 

(313.4

)

Income tax effect of reconciling items (11)

(32.0

)

 

 

(35.7

)

 

(106.4

)

 

(104.4

)

Non-GAAP net income

$

415.7

 

 

$

542.6

 

 

$

2,182.4

 

 

$

1,049.8

 

Net loss attributable to non-controlling interest

—

 

 

 

(1.1

)

 

(1.8

)

 

(3.4

)

Net income attributable to Hologic

$

415.7

 

 

$

543.7

 

 

$

2,184.2

 

 

$

1,053.2

 

 

 

 

 

 

 

 

 

Net Income Percentage:

 

 

 

 

 

 

 

GAAP net income percentage

25.0

%

 

 

36.6

%

 

33.2

%

 

29.4

%

Impact of adjustments above

6.6

%

 

 

3.8

%

 

5.6

%

 

(1.5

)%

Non-GAAP net income attributable to Hologic percentage

31.6

%

 

 

40.4

%

 

38.8

%

 

27.9

%

 

 

 

 

 

 

 

 

Earnings per Share Attributable to Hologic:

 

 

 

 

 

 

 

GAAP income per share - Diluted

$

1.28

 

 

$

1.88

 

 

$

7.21

 

 

$

4.21

 

Adjustment to net income (as detailed above)

0.33

 

 

$

0.19

 

 

1.20

 

 

(0.23

)

Non-GAAP earnings per share – diluted (12)

$

1.61

 

 

$

2.07

 

 

$

8.41

 

 

$

3.98

 

 

 

 

 

 

 

 

 

Adjusted EBITDA:

 

 

 

 

 

 

 

Non-GAAP net income

$

415.7

 

 

$

543.7

 

 

$

2,184.2

 

 

$

1,053.2

 

Interest expense, net, not adjusted above

22.5

 

 

 

24.7

 

 

86.5

 

 

112.2

 

Provision for income taxes

113.8

 

 

 

159.8

 

 

597.7

 

 

309.1

 

Depreciation expense, not adjusted above

23.8

 

 

 

20.3

 

 

88.0

 

 

83.1

 

Adjusted EBITDA

$

575.8

 

 

$

748.5

 

 

$

2,956.4

 

 

$

1,557.6

 

Explanatory Notes to Reconciliations:

(1)


To reflect non-cash expenses attributable to the amortization of acquired intangible assets.

(2)


To reflect the exclusion of third party expenses incurred to obtain compliance with the European Medical Device Regulation requirement for the Company's existing products for which it already has FDA approval and/or CE mark.

(3)


To reflect restructuring and divestiture charges, and certain costs associated with the Company’s integration and facility consolidation plans, which primarily include retention and transfer costs, as well as costs incurred to integrate acquisitions and dispose of businesses, including consulting, legal, tax and accounting fees. In addition, this category includes additional expenses incurred related to the Cynosure disposition, primarily settlements of litigation and indemnification provisions for legal and tax matters that existed as of the date of disposition.

(4)


To reflect expenses with third parties related to acquisitions and divestitures prior to when such transactions are completed. These expenses primarily comprise broker fees, legal fees, consulting and due diligence fees, and a transfer tax related to the Mobidiag acquisition.

(5)


To reflect non-income tax charges, settlements and benefits, including from a statute of limitations expiration, related to prior years' matters.

(6)


To reflect a debt extinguishment loss from refinancing the 2025 Senior Notes.

(7)


To reflect adjustments to the estimated contingent consideration liabilities related to the Acessa Health and Faxitron acquisitions in fiscal 2021 and 2020, respectively, which are payable upon meeting defined revenue growth metrics.

(8)


To reflect non-cash unrealized gains and losses on the mark-to-market on outstanding forward foreign currency and option contracts, which do not qualify for hedge accounting.

(9)


To reflect the amount of debt issuance costs recorded directly to interest expense as a result of refinancing the 2025 Senior Notes.

(10)


To reflect an adjustment for the final Faxitron hold-back payment and an adjustment to reduce certain acquired accruals in fiscal 2020.

(11)


To reflect an estimated annual effective tax rate of 21.50% and 22.75% for fiscal 2021 and 2020, respectively.

(12)


Non-GAAP earnings per share was calculated based on 257,710 and 259,706 weighted average diluted shares outstanding for the three and twelve months ended September 25, 2021, respectively, and 263,179 and 264,613 for the three and twelve months ended September 26, 2020, respectively.

(13)


To reflect the fair value step up of inventory sold during the period related to the Somatex, Acessa Health, Diagenode and Mobidiag acquisitions in fiscal 2021 and the SuperSonic Imagine and Health Beacons acquisitions in fiscal 2020, respectively.

(14)


To reflect an impairment of a cost method equity investment.

(15)


To reflect a gain of $1.5 million to remeasure the Company's initial investment in SuperSonic Imagine pursuant to U.S. GAAP for purchase accounting, partially offset by a charge of $0.5 million for the sale of an investment security.

(16)


To reflect recording the Cynosure business to fair value based upon meeting the assets-held-for-sale criteria in the first quarter of fiscal 2020 due to executing an agreement to sell the business.

(17)


To reflect a discrete tax benefit from the sale of Cynosure.

(18)


To reflect the purchase of intangible assets to be used in a research and development project that has no future alternative use.

Reconciliation of GAAP to non-GAAP EPS Guidance:

 

Guidance Range
Quarter Ending
December 25, 2021

 

Guidance Range
Quarter Ending
September 24, 2022

 

Low

High

 

Low

High

GAAP Net Income Per Share

$

0.88

 

$

0.98

 

 

$

2.50

 

$

2.80

 

Amortization of acquired intangible assets

 

0.32

 

 

0.32

 

 

 

1.26

 

 

1.26

 

Other charges

 

0.02

 

 

0.02

 

 

 

0.08

 

 

0.08

 

Tax Impact of Exclusions

 

(0.07

)

 

(0.07

)

 

 

(0.29

)

 

(0.29

)

Non-GAAP Net Income Per Share

$

1.15


$

1.25


 

$

3.55


$ 

3.85 


 

Trailing Twelve Months ended
September 25, 2021

Return on Invested Capital:

 

 

 

Adjusted Net Operating Profit After Tax

 

Non-GAAP net income

$

2,184.2

 

Non-GAAP provision for income taxes

597.7

 

Non-GAAP interest expense

87.9

 

Non-GAAP other income

(2.2

)

Adjusted net operating profit before tax

$

2,867.6

 

Non-GAAP average effective tax rate (1)

21.50

%

Adjusted net operating profit after tax

$

2,251.1

 

 

 

Average Net Debt plus Average Stockholders’ Equity (2)

 

Average total debt

$

3,032.0

 

Less: Average cash and cash equivalents

(935.7

)

Average net debt

2,096.3

 

Average stockholders’ equity (3)

4,813.7

 

Average net debt plus average stockholders’ equity

$

6,910.0

 

 

 

Adjusted ROIC

 

Adjusted ROIC (adjusted net operating profit after tax above divided by average net debt plus stockholders’ equity above)

32.6

%

(1)


ROIC is presented on a TTM basis; non-GAAP effective tax rate for the twelve months ended September 25, 2021 was 21.50%.

(2)


Calculated using the average of the balances as of September 25, 2021 and September 26, 2020.

(3)


Adjusted (increased) to eliminate the effect of the impairment of intangible assets of $32.2 million in fiscal 2014, the impairment of goodwill of $685.7 million and an IPR&D asset of $46.0 million in fiscal 2018, the impairment of intangible assets and equipment of $685.4 million in fiscal 2019, and the impairment of intangible assets and equipment of $30.2 million in fiscal 2020. The impact of the intangible asset impairment charges is reflected net of tax.

 

As of

 

September 25, 2021

Leverage Ratio:

 

 

 

Total principal debt

$

3,050.5

 

Total cash

(1,170.3)

 

Net principal debt, as adjusted

$

1,880.2

 

EBITDA for the last four quarters

$

2,956.4

 

Leverage Ratio

0.6

 

Other Supplemental Information:

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Twelve Months Ended

 

 

September 25,
2021

 

September 26,
2020

 

September 25,
2021

 

September 26,
2020

 

 

 

 

 

 

 

 

 

Geographic Revenues

 

 

 

 

 

 

 

 

U.S.

 

72.2

%

 

73.9

%

 

69.3

%

 

75.8

%

Europe

 

18.0

%

 

18.3

%

 

21.3

%

 

15.1

%

Asia-Pacific

 

7.4

%

 

5.3

%

 

6.5

%

 

6.0

%

All Others

 

2.4

%

 

2.5

%

 

2.9

%

 

3.1

%

Total Revenues

 

100.0

%

 

100.0

%

 

100.0

%

 

100.0

%

 

Contacts

Michael Watts
Vice President, Investor Relations and Corporate Communications
(858) 410-8588
Michael.Watts@hologic.com

Ryan Simon
Vice President, Investor Relations
(858) 410-8514
Ryan.Simon@hologic.com

EX-101.SCH 3 holx-20211101.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 holx-20211101_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 holx-20211101_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 a52518777_htm.xml IDEA: XBRL DOCUMENT 0000859737 2021-11-01 2021-11-01 false 0000859737 8-K 2021-11-01 HOLOGIC, INC. DE 001-36214 04-2902449 250 Campus Drive Marlborough MA 01752 508 263-2900 false false false false Common Stock HOLX NASDAQ false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 01, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 01, 2021
Entity Registrant Name HOLOGIC, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36214
Entity Tax Identification Number 04-2902449
Entity Address, Address Line One 250 Campus Drive
Entity Address, City or Town Marlborough
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01752
City Area Code 508
Local Phone Number 263-2900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000859737
Title of 12(b) Security Common Stock
Trading Symbol HOLX
Security Exchange Name NASDAQ
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://hologic.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports a52518777.htm a52518777_ex991.htm holx-20211101.xsd holx-20211101_lab.xml holx-20211101_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a52518777.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "a52518777.htm" ] }, "labelLink": { "local": [ "holx-20211101_lab.xml" ] }, "presentationLink": { "local": [ "holx-20211101_pre.xml" ] }, "schema": { "local": [ "holx-20211101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "holx", "nsuri": "http://hologic.com/20211101", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a52518777.htm", "contextRef": "c20211101to20211101", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://hologic.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a52518777.htm", "contextRef": "c20211101to20211101", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://hologic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001157523-21-001297-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001157523-21-001297-xbrl.zip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�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end